FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587010564> ?p ?o ?g. }

• W2587010564 endingPage "4601" @default.
• W2587010564 startingPage "4601" @default.
• W2587010564 abstract "4601 Background: Hypertension (HTN) due to sunitinib is a common toxicity that has been linked to the development of severe adverse cardiovascular events. Intriguingly, recent observations also suggest a correlation between treatment related HTN and treatment response to anti-angiogenic therapies, including sunitinib. Risk predictors for the development of HTN have not been established. Methods: This is a single-arm phase II trial with a two-stage design to evaluate sunitinib (50 mg daily, 4/2 schedule) in non clear cell RCC (nccRCC). Eligibility criteria included PS 0-2, measurable disease, and a maximum of 2 prior regimens. Monitoring of cardiovascular events included coronary artery disease (CAD) risk-factor assessment and prospective monitoring of blood pressure and cardiac function. In addition, a panel of circulating angiogenic factors was measured prior to therapy and after the first cycle of therapy. Results: 46 pts (65% male, 26% >65 years of age) received an average of 2.6 cycles of sunitinib therapy for nccRCC from March 2007 to December 2009. There were 28 deaths (61%) which were due to progression of disease. 33% of pts developed Grade 2 or higher treatment-related HTN. 0/12 patients without established risk factors for CAD developed treatment related HTN, while 74% (13/17) of pts with two or more CAD risk factors developed treatment-related hypertension. Treatment with sunitinib was associated with a marked reduction in circulating VEGFR-2 levels after one cycle of treatment (p < 1 × 10-10). Intriguingly, baseline levels of soluble VGEFR-2 were two-fold lower in pts who developed treatment-related HTN (p < 0.05). An association between objective response rate and the development of HTN is being explored. Conclusions: HTN associated with sunitinib was observed at a much higher frequency in patients with underlying CAD risk factors. Soluble VEGFR-2 was significantly reduced after treatment in all patients, and was reduced at baseline in pts who developed treatment related HTN. Our observations suggest a complex and potentially important biological interaction between the host vasculature, tumor, and response to sunitinib therapy. No significant financial relationships to disclose." @default.
• W2587010564 created "2017-02-17" @default.
• W2587010564 creator A5034430161 @default.
• W2587010564 creator A5058115259 @default.
• W2587010564 creator A5068987389 @default.
• W2587010564 date "2010-05-20" @default.
• W2587010564 modified "2023-09-25" @default.
• W2587010564 title "A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib." @default.
• W2587010564 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.4601" @default.
• W2587010564 hasPublicationYear "2010" @default.
• W2587010564 type Work @default.
• W2587010564 sameAs 2587010564 @default.
• W2587010564 citedByCount "5" @default.
• W2587010564 countsByYear W25870105642012 @default.
• W2587010564 crossrefType "journal-article" @default.
• W2587010564 hasAuthorship W2587010564A5034430161 @default.
• W2587010564 hasAuthorship W2587010564A5058115259 @default.
• W2587010564 hasAuthorship W2587010564A5068987389 @default.
• W2587010564 hasConcept C126322002 @default.
• W2587010564 hasConcept C143998085 @default.
• W2587010564 hasConcept C197934379 @default.
• W2587010564 hasConcept C2777288759 @default.
• W2587010564 hasConcept C2777472916 @default.
• W2587010564 hasConcept C2778213512 @default.
• W2587010564 hasConcept C2779134260 @default.
• W2587010564 hasConcept C2779490328 @default.
• W2587010564 hasConcept C50440223 @default.
• W2587010564 hasConcept C71924100 @default.
• W2587010564 hasConcept C84393581 @default.
• W2587010564 hasConceptScore W2587010564C126322002 @default.
• W2587010564 hasConceptScore W2587010564C143998085 @default.
• W2587010564 hasConceptScore W2587010564C197934379 @default.
• W2587010564 hasConceptScore W2587010564C2777288759 @default.
• W2587010564 hasConceptScore W2587010564C2777472916 @default.
• W2587010564 hasConceptScore W2587010564C2778213512 @default.
• W2587010564 hasConceptScore W2587010564C2779134260 @default.
• W2587010564 hasConceptScore W2587010564C2779490328 @default.
• W2587010564 hasConceptScore W2587010564C50440223 @default.
• W2587010564 hasConceptScore W2587010564C71924100 @default.
• W2587010564 hasConceptScore W2587010564C84393581 @default.
• W2587010564 hasIssue "15_suppl" @default.
• W2587010564 hasLocation W25870105641 @default.
• W2587010564 hasOpenAccess W2587010564 @default.
• W2587010564 hasPrimaryLocation W25870105641 @default.
• W2587010564 hasRelatedWork W1895933560 @default.
• W2587010564 hasRelatedWork W2056402925 @default.
• W2587010564 hasRelatedWork W2072245035 @default.
• W2587010564 hasRelatedWork W2171237277 @default.
• W2587010564 hasRelatedWork W2544140097 @default.
• W2587010564 hasRelatedWork W2805430385 @default.
• W2587010564 hasRelatedWork W2971476881 @default.
• W2587010564 hasRelatedWork W3151554875 @default.
• W2587010564 hasRelatedWork W4205243027 @default.
• W2587010564 hasRelatedWork W4205299447 @default.
• W2587010564 hasVolume "28" @default.
• W2587010564 isParatext "false" @default.
• W2587010564 isRetracted "false" @default.
• W2587010564 magId "2587010564" @default.
• W2587010564 workType "article" @default.